Forecast

Buy	0
Hold	0
Sell	1

News Go to news feed

Euroapi to mothball metamizole production in Frankfurt and cut workforce

Euroapi will mothball its production facility for the painkiller metamizole in Frankfurt-Höchst at the end of the year and reduce the number of employees on site from around 750 to under 700. The company is withdrawing from several active ingredients for price-competitiveness reasons and plans to stepwise exit 13 substances by 2027. Across Europe many active-ingredient productions have been shifted in favor of Asian suppliers, which is why France is providing state funds to modernize Euroapi sites. Policymakers and industry are now debating subsidy programs and procurement rules to strengthen supply security and local value creation in active-ingredient production. » More on faz.net

Financials

In the last quarter, EUROAPI had revenue of 355.97m€ and net profit of −141.29m€

(EUR)	Jun 2026	YoY
Revenue	+355.97m	-
Gross profit	+55.72m	-
Net profit	−141.29m	-
EBITDA	+83.77m	-

Fundamentals

Metric	Value
Market capitalization	+140.24m€
Number of shares	95.57m
52-week high/low	+3,08€ - +1,00€
Dividends	No
Beta	0,98
P/E ratio	−0,28
PEG ratio	0,00
P/B ratio	+0,19
P/S ratio	+0,11

Company profile

Euroapi SA entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Paris, Frankreich.